Navarrete, AndresMomblan, DulceAlmenara, RaulLacy, Antonio2017-08-162017-08-162016J Gastrointest Surg (2017) 21:202-204http://hdl.handle.net/11447/1578http://dx.doi.org/10.1007/s11605-016-3196-xGastrointestinal stromal tumors (GIST) represent 0.1–3 % of gastrointestinal malignancy. Surgery is the mainstay of treatment, but in high-risk tumors, imatinib can help to achieve better oncological outcomes. We present a rare case of a patient with gastric GIST with very aggressive evolution in a short period of time despite the use of neoadjuvant therapy with imatinib.3en-USGISTGastricImatinibArtículo